The MHRA Papers - Part 2

We have some questions, but there is no formal obligation to reply

We continue reviewing the minutes of the three meetings of the MHRA’s ​​Commission On Human Medicines (CHM) COVID-19 Vaccines Benefit Risk Expert Working Group, which took place between 28 October and 18 November 2020.

During the first meeting, the EWG reviewed the non-clinical and clinical evidence from trial BNT162b2 (Pfizer Biontech). As you may recal…